
# Imaging of the mitral valve for screening: Echo vs TEE vs Stress Echo

Rhonda Miyasaka, MD Section of Cardiovascular Imaging Cleveland Clinic

#### Management of Mitral Regurgitation 2020 ACC/AHA valve guidelines




## Evaluation of MR: TTE is your workhorse

#### MR severity

#### MR mechanism

#### LV size and function

#### Estimation of PA pressure



#### Diagnosis

#### Change in Sx

#### Routine follow up

## MR severity

## Qualitative

Method	Description	Example	Definition of Severe
Jet area	Apical view. Measure largest jet area compared to left atrial area	MR area 7.7 cm2 LA area 2.7 cm2 Jet area % = 37.2%	>50% LA
Flow convergence	Shift the Nyquist baseline in the direction of the regurgitant jet to see hemispheric flow convergence. Measure PISA radius from vena contracta to point of color aliasing.	PiSA radius 0.92 cm	Large, holosystolic
CW jet	Align CW with MR jet		Dense, holosystolic, triangular

### Semi quantitative


Method	Description	Example	Definition of Severe
Vena contracta width	The narrowest segment of the color jet, typically at the level of the regurgitant orifice.	Vena Contracta 0.9 cm	> 0.7 cm
Pulmonary vein flow	PW 1 cm into pulmonary vein		Systolic flow reversal
Mitral inflow	PW at the leaflet tips in the apical four chamber view		E velocity >1.2 m/s E wave dominant


## MR severity

## Quantitative

Variables needed







PISA radius (r)

Peak velocity MR jet (PKV<sub>reg</sub>)


MR VTI (VTI<sub>reg</sub>)

Parameter	Equation	Sample calculation
Regurgitant flow (Rflow, mL/sec)	$2\pi r^2 x Va$	2π(0.85) <sup>2</sup> x 0.37 = 1.67 mL/sec
EROA (cm <sup>2</sup> )	Rflow/ $PKV_{reg}$	1.67/5.92= 0.28 cm <sup>2</sup>
Regurgitation volume (Reg vol, mL)	EROA x VTI <sub>reg</sub>	0.28 x 1.69 = 0.48 mL


Cutoffs for severe: EROA > 0.40 cm2 Rvol >60 mL

## Inaccuracies of PISA method


A: Non holosystolic MR




B: Non circular MR orifice



#### C: Multiple jets



## Case: 55 yo referred for evaluation of MR





Qualitative:


- Flail
- Large PISA
- Triangular dense CW

Semi Qualitative:

- VC 1 cm (> 0.7)
- PV reversal

#### Quantitative


- EROA 2.8 cm2
- RV 280 mL/beat





## MR mechanism

#### Degenerative Mitral Regurgitation (DMR, Primary MR)




• Prolapse

• Perforation


- Flail
- Papillary muscle rupture
- Calcific changes
- Endocarditis
- Rheumatic


### Functional Mitral Regurgitation (FMR, Secondary MR)




- Normal mitral leaflets but other forces cause dysfunction
- Several subtypes of FMR, and etiology may be mixed

## 3D TTE: Anterior leaflet prolapse and flail







Case: 65 yo patient presents with newly diagnosed, severe primary mitral regurgitation. Overall she feels well but she's noticed some dyspnea with her favorite activity – Jazzercise.



- Normal LV size and function, EF 65%
- Severe MR 2/2 posterior prolapse





#### Should Patients With Severe Degenerative Mitral Regurgitation Delay Surgery Until Symptoms Develop?

A. Marc Gillinov, MD, Tomislav Mihaljevic, MD, Eugene H. Blackstone, MD, Kristopher George, MD, Lars G. Svensson, MD, Edward R. Nowicki, MD, MS, Joseph F. Sabik III, MD, Penny L. Houghtaling, MS, and Brian Griffin, MD

Departments of Thoracic and Cardiovascular Surgery and Cardiovascular Medicine, Heart and Vascular Institute, and Department of Quantitative Health Sciences, Research Institute, Cleveland Clinic, Cleveland, Ohio

*Methods.* From January 1985 to January 2008, 4,586 patients had primary isolated mitral valve surgery for degenerative mitral regurgitation; 4,253 (93%) underwent repair. Preoperatively, 30% were in New York Heart Association (NYHA) class I (asymptomatic), 56% in class II, 13% in class III, and 2% in class IV. Multivariable analysis and propensity matching were used to assess association of symptoms (NYHA class) with cardiac structure and function and postoperative outcomes.





Fig 3. Survival according to New York Heart Association (NYHA) functional class. (A) Unadjusted survival. (Solid circles = class I; open circles = class II; triangles = class III; squares = class IV.) (B) Survival in propensity-matched groups. (Solid circles = class I; open circles = class II; triangles = class III/IV.)

Increasing NYHA functional class was associated with:

- Reduction in LV function
- Left atrial enlargement
- Atrial fibrillation
- Tricuspid regurgitation




111

IV

Hospital Mortality (%)

Case: 68 yo incidentally diagnosed with severe MR after a murmur was heard on exam. Asymptomatic.



1B-NR2. In asymptomatic patients with severe primary<br/>MR and LV systolic dysfunction (LVEF ≤60%,<br/>LVESD ≥40 mm) (Stage C2), mitral valve<br/>surgery is recommended.261,262,272,273,275,303-3052bC-LD5. In asymptomatic patients with severe primary<br/>MR and normal LV systolic function (LVEF >60%<br/>and LVESD <40 mm) (Stage C1) but with a<br/>progressive increase in LV size or decrease in<br/>EF on ≥3 serial imaging studies, mitral valve<br/>surgery may be considered irrespective of the<br/>probability of a successful and durable repair.310

Normal EF. But LV is dilated (LVESD > 40).

Vol. 54, No. 21, 2009 ISSN 0735-1097/09/\$36.00 doi:10.1016/j.jacc.2009.06.047

Valvular Heart Disease


#### Survival Implication of Left Ventricular End-Systolic Diameter in Mitral Regurgitation Due to Flail Leaflets

#### A Long-Term Follow-Up Multicenter Study

Christophe Tribouilloy, MD, PHD,\* Francesco Grigioni, MD, PHD,† Jean François Avierinos, MD,‡ Andrea Barbieri, MD,§ Dan Rusinaru, MD,\* Catherine Szymanski, MD,\* Marinella Ferlito, MD,† Laurence Tafanelli, MD,‡ Francesca Bursi, MD,§ Faouzi Trojette, MD,\* Angelo Branzi, MD,† Gilbert Habib, MD,‡ Maria G. Modena, MD,§ Maurice Enriquez-Sarano, MD,∥ on behalf of the MIDA Investigators

Amiens and Marseille, France; Bologna and Modena, Italy; and Rochester, Minnesota

#### Lower survival with LVESD > 40 mm



#### Echocardiographic Prediction of Survival After Surgical Correction of Organic Mitral Regurgitation

(Circulation. 1994;90:830-837.)

Maurice Enriquez-Sarano, MD; A. Jamil Tajik, MD; Hartzell V. Schaff, MD; Thomas A. Orszulak, MD; Kent R. Bailey, PhD; Robert L. Frye, MD

> *Methods and Results* The survival of 409 patients operated on between 1980 and 1989 for pure, isolated, organic mitral regurgitation and with a preoperative echocardiogram (within 6 months of operation) was analyzed. The overall survival was 75% at 5 years (90% of expected), 58% at 10 years (88% of







Fig 2. Graph of late survival of operative survivors according to preoperative echocardiographic ejection fraction (EF). Number at risk for each interval is indicated at bottom.

Case:

58 yo with mitral valve prolapse followed for years. Last echo showed severe MR. Asymptomatic, good exercise tolerance. Biplane EF 65%.










2a B-NR	4. In asymptomatic patients with severe primary MR and normal LV systolic function (LVEF ≥60% and LVESD ≤40 mm) (Stage C1), mitral valve repair is reasonable when the likelihood of a successful and durable repair without residual MR is >95% with an expected mortality rate of <1%, when it can be performed at a Primary or Comprehensive Valve Center. <sup>273,308,310</sup>
---------	--

#### **Original Investigation**

#### Association Between Early Surgical Intervention vs Watchful Waiting and Outcomes for Mitral Regurgitation Due to Flail Mitral Valve Leaflets


Rakesh M. Suri, MD, DPhil; Jean-Louis Vanoverschelde, MD; Francesco Grigioni, MD, PhD; Hartzell V. Schaff, MD; Christophe Tribouilloy, MD; Jean-Francois Avierinos, MD; Andrea Barbieri, MD; Agnes Pasquet, MD; Marianne Huebner, PhD; Dan Rusinaru, MD; Antonio Russo, MD; Hector I. Michelena, MD; Maurice Enriquez-Sarano, MD *JAMA*. 2013;310(6):609-616. doi:10.1001/jama.2013.8643 **DESIGN, SETTING, AND PARTICIPANTS** The Mitral Regurgitation International Database (MIDA) registry includes 2097 consecutive patients with flail mitral valve regurgitation (1980-2004) receiving routine cardiac care from 6 tertiary centers (France, Italy, Belgium, and the United States). Mean follow-up was 10.3 years and was 98% complete. Of 1021 patients with mitral regurgitation without the American College of Cardiology (ACC) and the American Heart Association (AHA) guideline class I triggers, 575 patients were initially medically managed and 446 underwent mitral valve surgery within 3 months following detection.

#### Early surgery better survival



Long-term survival following early surgery vs initial medical management overall population (A) and in the propensity score-matched cohort (B).

#### Early surgery less CHF




Long-term heart failure risk following early surgery vs initial medical management overall (A) and in the propensity score-matched cohort (B).

Thus far, all of the cases have been determined by TTE and clinical findings, when do we need further testing like exercise echo?

#### **Exercise Echo**

- Clarify symptoms/functional status
- Evaluate for change in MR severity
- Evaluate for development of pulmonary hypertension
- Evaluate for contractile reserve

2a B-NR	<ol> <li>In patients with primary MR (Stages B and C) and symptoms that might be attributable to MR, hemodynamic exercise testing using Doppler echocardiography or cardiac catheterization or cardiopulmonary exercise testing is reasonable.<sup>290–293</sup></li> </ol>
---------	---





Leung DY, Griffin BP et al. Left ventricular function after valve repair for chronic mitral regurgitation: predictive value of preoperative assessment of contractile reserve by exercise echocardiography. J Am Coll Cardiol 1996;28:1198-205. Magne J et al. Impact of exercise pulmonary hypertension on postoperative outcome in primary mitral regurgitation. Heart 2015;101:391-6.

Case: 61-year-old gentleman with asymptomatic severe primary mitral regurgitation after a failed MV repair



4 METs





Courtesy of Serge Harb, MD

## When do we need TEE?

1	C-EO	<ol> <li>In patients with primary MR, when TTE provides insufficient or discordant inform TEE is indicated for evaluation of the sev of MR, mechanism of MR, and status of function (Stages B to D).</li> </ol>
		3 In patients with chronic secondary MR

1


B-NR

provides insufficient or discordant information, TEE is indicated for evaluation of the severity of MR, mechanism of MR, and status of LV function (Stages B to D).


3. In patients with chronic secondary MR with severe symptoms (Stage D) that are unresponsive to GDMT who are being considered for transcatheter mitral valve interventions, TEE is indicated to determine suitability for the procedure.3-8

- To clarify MR severity
- To clarify MR mechanism
- To determine intervention


## Case: 61 yo transferred to the cardiac ICU with respiratory failure after a late presenting STEMI



## TEE: Severe MR 2/2 ruptured pap muscle



## TEE to clarify procedural candidacy



#### Surgical interventions





FIGURE 6 Nonresectional mitral valve repair using premeasured chordal loops. A normal chord adjacent to the area of prolapse is measured with a caliper, establishing the desired length of the neochordal loops. The premeasured chordal loops are attached to the papillary muscle (A-B). Separate sutures are used to attach the loops to the leaflet edge in the area of the prolapse (C)

J Card Surg. 2019;34:717-727.

## When do we consider mitral TEER?


## **Primary MR**



anatomy is favorable for the repair procedure

and patient life expectancy is at least 1 year.311,312

## **Secondary MR**




related to LV systolic dysfunction (LVEF <50%) who have persistent severe symptoms (NYHA) class II, III, or IV) while on optimal GDMT for HF (Stage D), TEER is reasonable in patients with appropriate anatomy as defined on TEE and with LVEF between 20% and 50%, LVESD ≤70 mm, and pulmonary artery systolic pressure ≤70 mm Hg.<sup>318,338-344</sup>

2a

B-R

## How do we determine favorable anatomy? ASE guidelines



• Very comprehensive. Details every possible view of the mitral valve.

The key to structural imaging is understanding what questions are being asked and... *answer them*.

## Key Questions for M-TEER

Can we adequately reduce the MR?

#### • Where is the MR?

- Central vs medial or lateral
- Focal origin vs broad or multiple jets
- Are the leaflets graspable?





- Ideal mean gradient (<5 mmHg)
- Ideal MVA >4 cm2
- Rheumatic, radiation or calcific disease higher risk


Other procedural challenges?

- Complex anatomy?
- Transseptal puncture?
- Imaging challenges?

## Case: 91 yo with dyspnea on exertion, can no longer golf without stopping to catch his breath









## P2 prolapse and flail


## 3D imaging




## 3D MPR



## Are the leaflets graspable at P2?




What would our grasping view look like if we placed the clip like this?



We can then analyze this specific plane for "graspability"

- Leaflet length
- Chords
- Coaptation gap

## Will we cause mitral stenosis?




#### Goal MVA > 4 cm2


## Should we offer TEER?

RM TEE X8-2t 11Hz 9.7cm

3D Zoom



## FMR : patient selection is key




## FMR related to atrial fibrillation

78 yo admitted to outside hospital with CHF, found to be in afib with RVR. TTE with severe MR. Referred to for mitral valve intervention..




#### DCCV, diuresis $\rightarrow$ trivial MR




Afib with RVR


## Severe LV dysfunction




## 65 yo with ischemic cardiomyopathy and severe functional MR. Symptomatic despite optimization.



Medical therapy	MitraClip	Advanced therapy
GDMT Revascularization CRT LV size/function may improve Symptoms may improve MR may improve	Optimal therapy EF 20-50% Severe MR NYHA III-IV	Ventricle is too sick MR is not primary issue








Central MR Good leaflet length Large valve, MG 1

Good anatomy for M-TEER

## Successful MitraClip at A2/P2









## Why might a patient not be a candidate for TEER?

#### MR origin too wide



## C D D D

Can't zipper the valve shut




#### 20Hz 73cm 90 Jacon 90

If MS present preprocedurally, TEER will only make worse

# Posterior leaflet too short 3D Beats 1

Goal, leaflet length > 7 mm

## Anatomic considerations that may increase procedural complexity



## Summary

- TTE is the primary imaging modality used to diagnose and monitor mitral regurgitation
- Treadmill echo is useful when there's a discrepancy between clinical symptoms and MR severity
- TEE is useful to further define MR severity, MR mechanism and plan for intervention

## Thank You